Neutralizing antibodies elicited in nonhuman primates by an enterovirus D68 virus-like particle vaccine target

Daniel L Moss1, Jiaxuan Cheng1, Peter W Krug1

  • 1Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892, USA.

Insights

Monoclonal antibodies targeting Enterovirus D68 (EV-D68) virus-like particles (VLPs) show potent neutralization and protection in animal models. These antibodies disrupt viral entry and uncoating, highlighting VLP-based vaccines as a promising countermeasure for EV-D68.

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Enterovirus D68 (EV-D68) causes respiratory illness in children, with potential for severe complications like acute flaccid myelitis (AFM).
  • EV-D68 virus-like particles (VLPs) are known to induce protective neutralizing antibodies in preclinical models.

Purpose of the Study:

  • To isolate and characterize monoclonal antibodies (mAbs) against EV-D68 elicited by VLP immunization in nonhuman primates (NHPs).
  • To elucidate the neutralization mechanisms and epitope targets of these VLP-elicited mAbs.

Main Methods:

  • Isolation and characterization of mAbs from immunized NHPs.
  • Cryo-electron microscopy (cryo-EM) to determine mAb-VLP complex structures.
  • In vivo challenge studies in a mouse model to assess protective efficacy.

Main Results:

  • Five potent neutralizing mAbs were identified, targeting epitopes near the capsid's fivefold axis.
  • Cryo-EM revealed mAb epitopes bridging sialic acid and receptor binding sites.
  • mAbs demonstrated neutralization by disrupting multiple EV-D68 life cycle steps, including premature uncoating.
  • VLP-elicited antibodies provided protection comparable to a human mAb in a mouse model, though viral escape was observed via single-amino acid mutations.

Conclusions:

  • EV-D68 VLP-elicited mAbs target critical viral vulnerabilities and offer insights into neutralization mechanisms.
  • These findings support the potential of VLP-based vaccines as effective countermeasures against EV-D68 infections.